Navigation Links
R. Lindholm Named to Crux Biomedical Board
Date:3/14/2011

MENLO PARK, Calif., March 14, 2011 /PRNewswire/ -- Crux Biomedical, developer of an advanced implantable vena cava filter (IVCF) to prevent pulmonary embolisms, announced the appointment of Randy Lindholm to its Board of Directors. Mr. Lindholm is a widely respected advisor to the medical device field. He was previously Chairman and CEO of Vidamed,  a maker of minimally invasive medical devices to treat benign prostate hyperplasia until it was acquired by Medtronic in 2002.  Prior to Vidamed, Randy held senior positions at Nellcor Puritan Bennett and GE Medical Systems. " I am excited to join Crux Biomedical. They are well positioned to take advantage of the current interest in a better performing retrievable IVC filter," stated Mr. Lindholm. He currently serves as director of publically held Omnicell (MLCL), Barrx Medical, Tibion Bionic Technologies, Estech and Novasys Medical.

"We are very pleased to have Randy's operating experience at Crux," states Mel Schatz, CEO of Crux Biomedical. He continued, "Randy has assisted numerous firms in securing venture backed funding."  Crux Biomedical is currently enrolling patients in its pivotal IDE study in the United States and several sites internationally. It expects to complete the U.S. study in 2011 and launch internationally  later this year.

Crux Biomedical was founded in 2004 by Thomas Fogarty, M.D., to target the development of an advanced implantable inferior vena cava filter (IVCF) to prevent the occurrence of potentially fatal pulmonary embolisms. Although routinely used in the United States, currently cleared IVC filters are associated with a variety of complications. "We recognized current IVC filters did not meet the needs of clinicians and designed a filter that provided better retrievability," stated Tom Fogarty, M.D.

Each year in the United States approximately 600,000 patients develop a PE and an estimated 200,000 deaths occur. Pulmonary embolisms are recognized a
'/>"/>

SOURCE Crux Biomedical
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
2. Michael Petras, Former CEO of GE Lighting, Named CEO of Cleveland-Based Specialty Medical Supplies Leader
3. Living Medical eTextbook iPhone App from Projects In Knowledge® Named to Top 20 List of Free Medical Apps
4. Dawn Phillips Named as Vice President, Business Development for Catastrophic & Home Health Services
5. Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman of the Year by The Healthcare Businesswomens Association
6. Dynatronics Named Contract Supplier to Amerinets 50,000 Members
7. R&J Public Relations Named Agency of Record for Aerocrine, Inc.
8. Stryker Corporation Named One of FORTUNE Magazines 100 Best Companies to Work For
9. Kevin Banion Named CEO of Progressive Medical, Inc.
10. Webmedx Named Best in KLAS and Ranked #1 Transcription Services Vendor for Second Year in a Row
11. Elektas MOSAIQ Oncology Information System Named Category Leader in 2010 Top 20 Best in KLAS Awards Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... Mass. , Feb. 27, 2015   Synageva ... ), a biopharmaceutical company developing therapeutic products for ... Disorders™ (NORD™), the European Organisation for Rare Diseases™ ... the world in observing Rare Disease Day. ... year, patient organizations, industry, and other participants conduct ...
(Date:2/27/2015)... 27, 2015 ... für kongestive Herzinsuffizienz (CHF) in seiner ersten ...     Die israelische ... Herzüberwachungssystem für Patienten mit kongestiver Herzinsuffizienz (CHF) ... ein Finanzierungsvorhaben über 5 Mio. USD abgeschlossen ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 2Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 3Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 4Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 5Synageva BioPharma Joins NORD, EURORDIS, And The Global Genes Project In Support Of Rare Disease Day 2015 6Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2
... ANNAPOLIS, Md., March 31 PharmAthene, Inc. (NYSE Amex: ... against biological and chemical threats, announced today that new ... the Keystone Symposia on Molecular and Cellular Biology Conference ... Alberta. The data were presented by Dr. Alan ...
... 31 QuatRx Pharmaceuticals, a privately-held biopharmaceutical company, today ... second pivotal Phase 3 clinical trial of Ophena(TM) ... pivotal Phase 3 study of Ophena(TM) , the ... studies for Ophena(TM) , the most advanced estrogen-free ...
Cached Medicine Technology:Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology 2Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology 3Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology 4Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology 5Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology 6QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 2QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy 3
(Date:2/28/2015)... (PRWEB) March 01, 2015 Heart diseases ... that 10 percent of urban adult population and 5 ... of heart diseases and 20-30 percent of them require ... heart ailments and coronary vascular diseases (CVD). , A ... a new market research report titled “Indian Coronary Stent ...
(Date:2/28/2015)... 2015 The Heart Fit Clinic started ... of the machine. The Heart Fit Clinic is also ... a franchise model. The goal is to scale the ... disease. To buy External Counterpulsation machines can ... individuals through this process and achieve the desired results. ...
(Date:2/28/2015)... Vancouver personal injury lawyers at Jiwa Law Corporation recently ... limits. They stated that in many cases, missing an important ... it. Many a time, delays in making an injury claim ... law. As a result, experts at Jiwa Law Corporation suggest ... personal injury lawyer in order to know more about their ...
(Date:2/28/2015)... The Mesothelioma Applied Research Foundation ... International Symposium on Malignant Mesothelioma on Monday, March 2. ... Regency Bethesda in Bethesda, Maryland. The following award recipients ... to the mission to cure mesothelioma. , The Klaus ... to Miriam Ratner. Miriam runs the Meso Foundation’s monthly ...
(Date:2/28/2015)... Orlando, FL (PRWEB) February 28, 2015 ... community organization has sponsored visitor health insurance programs for ... 25 years. Most Indian elderly parents traveling to the ... conditions such as diabetes and blood pressure. These diseases ... do not even list them as medical conditions. There ...
Breaking Medicine News(10 mins):Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 2Health News:India Coronary Stent Market 2019 Forecasts Analysis in New Research Report Available at MarketReportsOnline.com 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Jiwa Law Corporation Recently Announced That Time Delays May Weaken Personal Injury Claims 2Health News:Cancer Research Foundation Honors Award Recipients 2Health News:Cancer Research Foundation Honors Award Recipients 3Health News:Cancer Research Foundation Honors Award Recipients 4Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 2Health News:India Network Announces Pre-existing Condition Health Insurance Coverage for Diabetic Visitors of All Ages Traveling to the United States 3
... urinate, affects the quality of life of many women. ... can tolerate oral medications and may benefit from other therapies. ... is conducting a study to compare the effect of two ... trying other treatments. Patients are currently being enrolled in ...
... February 29, 2012 A new method for creating ... Institute of New York University (NYU-Poly), promises to greatly ... heart disorders and Alzheimer,s disease, as well as aid ... , In addition, applied differently, this same development could ...
... new way of measuring the potential success rate of an ... in vitro fertilisation (IVF). According to the findings published ... fluid within a woman,s ovaries that surrounds the egg or ... embryo is more likely to lead to pregnancy. "We ...
... TUESDAY, Feb. 28 (HealthDay News) -- Taking the hallucinogen ecstasy ... lead to poorer motor control in infants, a new study ... history before and during pregnancy. The women were taking part ... which looks at recreational drug use among pregnant women. Most ...
... elderly cancer patients are evolving as more of the population ... To address these issues and others, national thought leaders ... the Kimmel Cancer Center at Jefferson (KCC) in ... an overview of the latest advances in the understanding and ...
... all deaths in the United States are linked to behavioral ... Despite these causal links, of the $2 trillion spent annually ... that is devoted to addressing behavioral and social risk factors. ... behavioral and social sciences with a new $500,000 grant from ...
Cached Medicine News:Health News:Women & Infants studying therapies to relieve urinary urge incontinence 2Health News:Nanofiber breakthrough holds promise for medicine and microprocessors 2Health News:New test can better predict successful IVF embryos, scientists say 2Health News:Ecstasy Use During Pregnancy May Harm Fetus: Study 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 2Health News:A new battlefront: Symposium at Jefferson's Kimmel Cancer Center to tackle geriatric oncology 3Health News:Training grant targets behavioral and social factors linked to health 2Health News:Training grant targets behavioral and social factors linked to health 3
POLYSORB™ sutures are composed of LACTOMER™ glycolide/lactide copolymer which is a synthetic polyester composed of glycolide and lactide (derived from glycolic and lactic acids)....
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO SLIDE™ single use knot pusher with 12 units per box....
ENDO STITCH™ Single Use Loading Units....
Medicine Products: